- Hamilton Thorne (HTL) appoints Francesco Fragasso as CFO
- Fragasso replaces retiring CFO, Michael Bruns
- Hamilton Thorne is a global leading provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in ART, research, and cell biology markets
- Hamilton Thorne (HTL) is up today by 1.33 per cent, currently trading at C$1.52
Hamilton Thorne (HTL), a leading provider in the Assisted Reproductive Technologies (ART) market, has appointed Francesco Fragasso as the new CFO.
Effective September, Francesco Fragasso will replace Michael Bruns.
David Wolf, President and Chief Executive Officer commented on the appointment.
“We welcome the opportunity to add individuals with operational experience […] I look forward to working closely with Francesco as Hamilton Thorne continues growing its business.”
Fragasso is currently serving as the CFO of Fluence Corporation. He is responsible for all aspects of the company’s global financial operations, reporting, accounting, treasury, administration, planning, and internal controls. Before that, he was the CFO of Desalitech as well as Nuvera Fuel Cells.
Fragasso has held several executive positions and continues to play a critical role in developing and implementing the company’s global strategy.
Fragasso has his Bachelor’s and Master’s Degrees in Business and Finance from Universita’ Bocconi, Italy, and an MBA from Boston University School of Management.
“I would like to personally thank and recognize Michael Bruns for his significant and continued contributions to Hamilton Thorne.” Wolf carried on to say, “we grew during his tenure from a niche ART equipment provider with under $7 million of revenues to one of the leaders in our field. Even though Michael is retiring as CFO, he will continue to serve the company as a valued member of our growing finance group.”
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in ART, research, and cell biology markets.
Hamilton Thorne (HTL) is up today by 1.33 per cent, currently trading at C$1.52.